Swedish Orphan Biovitrum Investor Relations Material
Latest events
Q4 2024
Swedish Orphan Biovitrum
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Swedish Orphan Biovitrum
Access all reports
Segment Data
Access more data
Revenue by
Business area
Haematology
Immunology
Specialty Care
Expenses by
Financials
Swedish Orphan Biovitrum AB, an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. The company operates through three segments: Haemophilia & Hereditary Diseases, Inflammation & Immunology, and Other. It offers Alprolix for hemophilia B; Elocta to treat hemophilia A; Doptelet for thrombocytopenia; Kineret for rheumatoid arthritis; Thiola for cystinuria; Xultophy Cartridge that is used with Flexpen for treatment of diabetes; and Velphoro for hyperphosphatemia.
Key slides for Swedish Orphan Biovitrum
Q4 2024
Swedish Orphan Biovitrum
Q3 2024
Swedish Orphan Biovitrum
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
SOBI
Country
🇸🇪 Sweden